Who are the top shareholders of the Brooks Lab.?

The top shareholders of Brooks Lab include Atul Ranchal with 19.24%, Quant Mutual Fund at 9.9%, and individual investors collectively holding 31.86%. Foreign institutional investors hold a minimal 0.05%.

The top shareholders of Brooks Lab include the promoters, with Atul Ranchal holding the highest individual stake at 19.24%. Additionally, Quant Mutual Fund, specifically through the Quant Business Cycle Fund, is the highest public shareholder with a holding of 9.9%. The company also has mutual funds holding 9.9% through one scheme and foreign institutional investors (FIIs) holding a minimal 0.05%. Individual investors collectively own 31.86% of the company.

how big is Brooks Lab.?

As of October 2023, Brooks Laboratories Ltd has a market capitalization of 393.70 Cr and reported net sales of 82.56 Cr with a net loss of 9.96 Cr over the last four quarters. Shareholder's funds are 65.59 Cr, and total assets amount to 90.45 Cr.

Market Cap: Brooks Laboratories Ltd has a market capitalization of 393.70 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which is consolidated data, amounts to 82.56 Cr. In contrast, the sum of Net Profit for the same period shows a loss of 9.96 Cr.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in March 2024. Shareholder's Funds are reported at 65.59 Cr, while Total Assets stand at 90.45 Cr.

Who are in the management team of Brooks Lab.?

As of March 2022, the management team of Brooks Lab includes Rajnish Kumar Bedi, Deepak Mahajan, and Sonia Gupta as Independent Directors, and Kaushalya Singh and Jitendra Pratap Singh as Whole Time Directors.

As of March 2022, the management team of Brooks Lab includes the following individuals:<BR><BR>1. Rajnish Kumar Bedi - Independent Director<BR>2. Deepak Mahajan - Independent Director<BR>3. Sonia Gupta - Independent Director<BR>4. Kaushalya Singh - Whole Time Director<BR>5. Jitendra Pratap Singh - Whole Time Director<BR><BR>These members play various roles within the company's governance and management structure.

What does Brooks Lab. do?

Brooks Laboratories Ltd is a pharmaceutical manufacturing company specializing in contract manufacturing of injectables, tablets, and dry syrups. As of March 2025, it reported net sales of 23 Cr and a net loss of 1 Cr, with a market cap of Rs 404 Cr.

Overview:<BR>Brooks Laboratories Ltd is a pharmaceutical manufacturing company operating in the Micro Cap segment of the Pharmaceuticals & Biotechnology industry, focusing on contract manufacturing of injectables, tablets, and dry syrups.<BR><BR>History:<BR>Brooks Laboratories Limited was incorporated on January 23, 2002. The company has been engaged in manufacturing for domestic customers and reported its latest quarterly results for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 23 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -1 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: Rs 404 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.06<BR>- Return on Equity: -10.15%<BR>- Price to Book: 4.14<BR><BR>Contact Details:<BR>Address: Village Kishanpura, Nilagarh Road Baddi Solan Himachal Pradesh : 174101<BR>Tel: 91-1795-654001/02/03<BR>Email: investors@brookslabs.net<BR>Website: http://www.brookslabs.net

Has Brooks Lab. declared dividend?

No Dividend History Available

Who are the peers of the Brooks Lab.?

Brooks Lab.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma. Brooks Lab. has below average management risk and growth, with a 1-year return of 83.44%, lower than Everest Organics' 252.60% but higher than Fredun Pharma's -8.48%.

Peers: The peers of Brooks Lab. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Everest Organics, SMS Lifesciences, Zenotech Lab., Fredun Pharma, and the rest. Below Average management risk is attributed to Brooks Lab. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Brooks Lab., Everest Organics, SMS Lifesciences, Zenotech Lab., and the rest. Average growth is noted at SMS Lifesciences, and good growth is observed at Fredun Pharma. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, while good capital structure is found at Torrent Pharma, average at SMS Lifesciences, and below average at Brooks Lab., Everest Organics, and Fredun Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the lowest is Fredun Pharma at -8.48%. Brooks Lab.'s 1-year return of 83.44% is significantly higher than Fredun Pharma's but lower than Everest Organics'. Additionally, peers with negative six-month returns include Cipla, Torrent Pharma, and Fredun Pharma.

When is the next results date for Brooks Lab.?

The next results date for Brooks Lab. is 13 August 2025.

The next results date for Brooks Lab. is scheduled for 13 August 2025.

Are Brooks Lab. latest results good or bad?

Brooks Laboratories' latest financial results are very positive, showing a profit before tax of Rs 9.36 crore, a 449.9% increase, and record net sales of Rs 25.51 crore, up 23.6%. Overall, these results indicate a significant turnaround in profitability and improved efficiency.

Brooks Laboratories has reported very strong financial results for the quarter ending June 2025, indicating a significant turnaround in profitability. The company achieved a profit before tax of Rs 9.36 crore, which is a remarkable increase of 449.9% compared to the average of the previous four quarters. Similarly, the profit after tax surged to Rs 9.58 crore, reflecting an increase of 484.7%.<BR><BR>Net sales also reached a record high of Rs 25.51 crore, growing by 23.6% over the previous four-quarter average. The operating profit stood at Rs 3.12 crore, with an operating profit margin of 12.23%, showcasing improved efficiency.<BR><BR>Additionally, earnings per share rose to Rs 3.25, the highest in five quarters. Overall, these results indicate a positive trend for Brooks Laboratories, suggesting that the latest financial performance is indeed good.

Is Brooks Lab. overvalued or undervalued?

As of October 20, 2025, Brooks Lab. is considered overvalued with a high PE ratio of 173.77 and an EV to EBITDA of 46.27, alongside poor financial performance and a year-to-date stock decline of 35.25%, making it an unfavorable investment at its current price of 119.75.

As of 20 October 2025, the valuation grade for Brooks Lab. has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on key financial metrics. The PE ratio stands at an exceptionally high 173.77, while the EV to EBITDA ratio is 46.27, both of which are significantly higher than its peers. In contrast, Sun Pharma has a PE ratio of 35.32 and an EV to EBITDA of 23.96, while Cipla, considered attractive, has a PE of 24.56 and an EV to EBITDA of 17.35.<BR><BR>Overall, Brooks Lab. appears to be overvalued given its high valuation ratios and poor financial performance, including a negative ROE of -10.15% and a low ROCE of 3.18%. Recent stock performance has also been disappointing, with a year-to-date decline of 35.25%, compared to a 7.97% increase in the Sensex, further reinforcing the notion that the stock is not a favorable investment at its current price of 119.75.

How has been the historical performance of Brooks Lab.?

Brooks Lab's historical performance shows a recovery in net sales from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, alongside improved operating profit of 4.94 Cr, despite a consolidated net loss of -9.97 Cr in Mar'25. Total assets increased to 123.69 Cr, and cash flow from operations turned positive at 2.00 Cr, indicating a potential turnaround.

Answer:<BR>The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar'25 from 90.45 Cr in Mar'24, while total liabilities also rose to 123.69 Cr in Mar'25, reflecting a stable financial position. Cash flow from operating activities turned positive at 2.00 Cr in Mar'25, contrasting with negative cash flows in previous years, indicating a potential turnaround in operational efficiency.

Should I buy, sell or hold Brooks Lab.?

Which are the latest news on Brooks Lab.?

Why is Brooks Lab. falling/rising?

As of 13-Dec, Brooks Laboratories Ltd's stock price is rising to 99.25, reflecting a 1.07% increase due to strong recent performance and positive financial results. However, despite short-term gains, the company faces weak long-term fundamentals with low return on equity and modest sales growth.

As of 13-Dec, Brooks Laboratories Ltd's stock price is rising, currently at 99.25, reflecting a change of 1.05 (1.07%) upward. This increase can be attributed to several factors. Notably, the stock has outperformed its sector by 1.02% today and has experienced consecutive gains over the last two days, accumulating a total return of 3.17% during this period. <BR><BR>Despite opening with a loss of -2.24% and touching an intraday low of Rs 96, the stock has managed to recover and rise above this low. The company has also reported positive financial results, including a growth in net sales of 4.06% and a significant increase in profit before tax, which has grown at an extraordinary rate of 2563.2% compared to the previous four-quarter average. Additionally, the company has declared positive results for the last four consecutive quarters, indicating consistent operational strength.<BR><BR>However, it is important to note that while the stock is currently rising, it has shown weak long-term fundamental strength, with a return on equity of only 2.42% and poor long-term growth, as net sales have grown at an annual rate of just 4.36% over the last five years. This context suggests that while there are short-term gains, the long-term outlook remains challenging.